This report analyzes the disruptive themes that have driven M&A activity in Q2 2025 in the pharma Sector.
The global pharma sector in Q2 2025 witnessed deals worth $36 billion, a growth of 14% compared to Q2 2024. The Pharma sector recorded deal value worth $29 billion mega deals (defined as any deal valued at more than $1 billion) in Q2 2025, an increase of 51% compared to Q2 2024.
The global pharma sector in Q2 2025 witnessed deals worth $36 billion, a growth of 14% compared to Q2 2024. The Pharma sector recorded deal value worth $29 billion mega deals (defined as any deal valued at more than $1 billion) in Q2 2025, an increase of 51% compared to Q2 2024.
Scope
- This report provides an overview of merger and acquisition activity globally in Q2 2025 in Pharma Sector
- It identifies the themes driving most notable to deals announced in Q2 2025 in the Pharma Sector
Reasons to Buy
- Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
- In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Table of Contents
- Executive Summary
- Review of the Pharma M&A Market - Q2 2025
- Pharma M&A Deals Analysis by Geography - Q2 2025
- Further Reading
- Appendix 1: Deal Selection Criteria
- Appendix 2: Thematic Research Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sanofi
- Merck KGaA
- AbbVie Inc
- GSK plc
- Novartis AG
- Torrent Pharmaceuticals Ltd
- Veraxa Biotech
- Eli Lilly and Co
- BioNTech SE
- RWK BidCo AB
- Shionogi & Co Ltd
- Eli Lilly and Co
- Supernus Pharmaceuticals Inc
- Sanofi
- Illumina Inc
- Clearbridge Health Ltd
- BioMarin Pharmaceutical Inc
- Neopharmed Gentili SpA
- Yangtze Investment (BVI) Ltd
- Haleon Plc
- Blueprint Medicines Corp
- SpringWorks Therapeutics Inc
- Capstan Therapeutics Inc
- Boston Pharma
- Regulus Therapeutics Inc
- J B Chemicals and Pharmaceuticals Ltd
- Voyager Acquisition
- Verve Therapeutics Inc
- Curevac NV
- Biotage AB
- Torii Pharmaceutical Co Ltd
- SiteOne Therapeutics Inc
- Sage Therapeutics Inc
- Vigil Neuroscience Inc
- SomaLogic Inc
- Elpis Biopharmaceuticals Pte Ltd
- Inozyme Pharma Inc
- BioCryst Pharma
- Probio Technology Ltd
- Tianjin TSKF Pharmaceutical Co Ltd
